Your browser is no longer supported. Please, upgrade your browser.
Settings
ARWR Arrowhead Pharmaceuticals, Inc. daily Stock Chart
ARWR [NASD]
Arrowhead Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.41 Insider Own2.20% Shs Outstand59.97M Perf Week3.79%
Market Cap82.15M Forward P/E- EPS next Y-0.75 Insider Trans-2.37% Shs Float56.78M Perf Month-77.58%
Income-84.20M PEG- EPS next Q-0.20 Inst Own50.70% Short Float17.60% Perf Quarter-80.87%
Sales0.20M P/S410.77 EPS this Y-28.30% Inst Trans46.51% Short Ratio6.63 Perf Half Y-76.58%
Book/sh1.00 P/B1.37 EPS next Y37.20% ROA-79.50% Target Price4.00 Perf Year-77.09%
Cash/sh0.74 P/C1.84 EPS next 5Y7.33% ROE-99.80% 52W Range1.32 - 8.22 Perf YTD-77.72%
Dividend- P/FCF- EPS past 5Y-26.90% ROI-86.50% 52W High-83.33% Beta2.09
Dividend %- Quick Ratio3.30 Sales past 5Y- Gross Margin- 52W Low3.79% ATR0.39
Employees104 Current Ratio3.30 Sales Q/Q-68.00% Oper. Margin- RSI (14)17.25 Volatility6.25% 9.30%
OptionableYes Debt/Eq0.06 EPS Q/Q-20.90% Profit Margin- Rel Volume0.78 Prev Close1.37
ShortableYes LT Debt/Eq0.05 EarningsDec 12 Payout- Avg Volume1.51M Price1.37
Recom3.00 SMA20-61.06% SMA50-74.44% SMA200-75.90% Volume1,174,279 Change0.00%
Nov-30-16Downgrade William Blair Outperform → Mkt Perform
Nov-30-16Downgrade Piper Jaffray Overweight → Neutral
Nov-30-16Downgrade Chardan Capital Markets Buy → Neutral $8 → $2
Nov-30-16Downgrade Cantor Fitzgerald Buy → Hold
Nov-10-16Reiterated Chardan Capital Markets Buy $10 → $8
Aug-18-16Initiated Cantor Fitzgerald Buy $15
May-19-16Initiated Chardan Capital Markets Buy $12
Sep-25-15Reiterated Piper Jaffray Overweight $12 → $20
Oct-09-14Downgrade RBC Capital Mkts Outperform → Sector Perform $35 → $9
Mar-05-14Initiated RBC Capital Mkts Outperform $35
Mar-05-14Initiated Deutsche Bank Buy $45
Feb-26-13Initiated Dawson James Buy $4
Dec-07-16 04:00PM  Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Year End Results Business Wire
01:28PM  SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Arrowhead Pharmaceuticals, Inc. and Reminds Investors with Losses to Contact the Firm Accesswire
11:25AM  EXPANDED CLASS PERIOD: Levi & Korsinsky, LLP Reminds Shareholders of Arrowhead Pharmaceuticals, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2017 ARWR GlobeNewswire
Dec-05-16 12:57PM  INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Arrowhead Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
10:10AM  SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Arrowhead Pharmaceuticals, Inc. (ARWR) & Lead Plaintiff Deadline: January 16, 2017 GlobeNewswire
Dec-04-16 01:04PM  7 of the Most Shocking Biotech Pipeline Blowups of 2016 at Motley Fool
Dec-02-16 09:43PM  INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Arrowhead Pharmaceuticals, Inc. and Reminds Investors with Losses to Contact the Firm Accesswire +9.09%
08:52PM  INVESTOR ALERT: Stull, Stull & Brody Filed a Securities Class Action Lawsuit on Behalf of Purchasers of Arrowhead Pharmaceuticals, Inc. Common Stock and Encourages Shareholders with Losses to Contact the Firm GlobeNewswire
Dec-01-16 04:46PM  ARROWHEAD PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events -8.33%
11:15AM  Arrowhead Halts 3 Drug Projects, Axes Jobs (ARWR) at Investopedia
Nov-30-16 06:48PM  SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Arrowhead Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire -67.20%
04:45PM  The Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Arrowhead Pharmaceuticals, Inc. Investors and Encourages Investors to Contact the Firm Business Wire
04:21PM  SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Arrowhead Pharmaceuticals, Inc. and Reminds Investors with Losses to Contact the Firm Accesswire
04:04PM  Arrowhead, Coca-Cola Lead Wednesdays 52-Week Low Club at 24/7 Wall St.
02:15PM  Arrowhead Shows Biotech Risks Come in Flavors at Bloomberg
12:54PM  Arrowhead Pharmaceuticals Inc (ARWR): Any Good Hearted Billionaires Out There (Willing To Pick Up Where Arrowhead Left Off)? at Insider Monkey
12:24PM  Here's Why Arrowhead Pharmaceuticals Inc. Is Being Obliterated Today at Motley Fool
10:35AM  Arrowhead Pharma Shares Destroyed by Development Announcement
10:24AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Arrowhead Pharmaceuticals, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2017 - ARWR Accesswire
08:40AM  Top Analyst Upgrades and Downgrades: Arrowhead Pharma, Cognizant, Goldman Sachs, HP, Splunk, UnitedHealth and More at 24/7 Wall St.
07:28AM  Arrowhead Pharma Downgraded Following EX-1 RNAi Program Discontinuations
06:03AM  Arrowhead downgraded by Chardan Capital Markets, Piper Jaffray, Cantor Fitzgerald and William Blair
Nov-29-16 04:47PM  Arrowhead Pharma shares plummet 60% on discontinued drug development at MarketWatch
04:03PM  Arrowhead Pharmaceuticals Focuses Resources on Subcutaneous and Extra-Hepatic RNAi Therapeutics Business Wire
12:29PM  INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Arrowhead Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
10:34AM  SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Arrowhead Pharmaceuticals, Inc. (ARWR) & Lead Plaintiff Deadline: January 16, 2017 Accesswire
Nov-25-16 06:11PM  INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Arrowhead Pharmaceuticals, Inc. and Reminds Investors with Losses to Contact the Firm Accesswire
02:51PM  INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Arrowhead Pharmaceuticals, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit Business Wire
02:29PM  SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Arrowhead Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
11:33AM  INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Arrowhead Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2017 -- ARWR Marketwired
10:34AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Arrowhead Pharmaceuticals, Inc. (ARWR) & Lead Plaintiff Deadline: January 16, 2017 Accesswire
06:00AM  IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Arrowhead Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
Nov-23-16 02:26PM  Robbins Arroyo LLP: Arrowhead Pharmaceuticals, Inc. (ARWR) Misled Shareholders According to a Recently Filed Class Action Business Wire
Nov-22-16 06:58PM  IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Arrowhead Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
02:03PM  ARWR LOSS ALERT: Rosen Law Firm Reminds Arrowhead Pharmaceuticals, Inc. Investors of Important Deadline in Class Action- ARWR PR Newswire
Nov-21-16 07:16PM  IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Arrowhead Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
03:45PM  ARWR SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Shareholders of a Class Action Involving Arrowhead Pharmaceuticals, Inc. and a Lead Plaintiff Deadline of January 17, 2017 GlobeNewswire
11:33AM  Arrowhead Pharmaceuticals Announces Closing of License and Collaboration Agreement with Amgen Business Wire
Nov-19-16 02:37PM  IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit Against Arrowhead Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm Business Wire
Nov-18-16 11:45PM  SHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Arrowhead Pharmaceuticals, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadl GlobeNewswire
09:38PM  SHAREHOLDER ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit against Arrowhead Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm Business Wire
08:00PM  Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Arrowhead Pharmaceuticals, Inc. (ARWR) GlobeNewswire
Nov-17-16 11:03AM  SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Arrowhead Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm Business Wire
10:10AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Arrowhead Pharmaceuticals, Inc. (ARWR) & Lead Plaintiff Deadline: January 16, 2017 GlobeNewswire
Nov-16-16 09:00PM  SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Arrowhead Pharmaceuticals, Inc. To Contact The Firm Before Lead Plaintiff Deadline GlobeNewswire -6.13%
04:58PM  IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Arrowhead Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm Business Wire
04:05PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Arrowhead Pharmaceuticals, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2017 ARWR GlobeNewswire
01:36PM  INVESTOR ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit against Arrowhead Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm Business Wire
12:30PM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Arrowhead Pharmaceuticals, Inc. (ARWR) & Lead Plaintiff Deadline: January 16, 2017 PR Newswire
12:12PM  INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Arrowhead Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm Business Wire
10:59AM  EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Arrowhead Pharmaceuticals, Inc. Business Wire
Nov-15-16 11:14PM  Pomerantz Law Firm Announces the Filing of a Class Action against Arrowhead Pharmaceuticals, Inc. and Certain Officers - ARWR GlobeNewswire +7.01%
Nov-14-16 03:00PM  Arrowhead Pharmaceuticals Presents New Data on ARC-F12 and ARC-LPA Using DPCsqTM Subcutaneous RNAi Delivery Vehicle Business Wire +5.74%
07:00AM  Arrowhead Pharmaceuticals Presents New Data on ARC-AAT Business Wire
Nov-12-16 09:46AM  4 Companies That Destroyed Shareholders Last Week at 24/7 Wall St.
Nov-11-16 12:55PM  IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces an Investigation of Arrowhead Pharmaceuticals, Inc. and Advises Investors with Losses to Contact the Firm Business Wire
12:15PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arrowhead Research Corp. - ARWR PR Newswire
03:01AM  Todays Movers And Shakers In Biotech: Arrowhead Pharmaceuticals Inc (ARWR) And Kite Pharma Inc (KITE) at Insider Monkey
Nov-10-16 03:47PM  What's Next for Arrowhead Pharmaceuticals, Inc. After the Stock Meltdown? at Motley Fool
06:04AM  ARROWHEAD PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Nov-09-16 08:53PM  SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of Arrowhead Pharmaceuticals, Inc. and Advises Investors with Losses to Contact the Firm Business Wire -31.26%
06:19PM  INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Arrowhead Pharmaceuticals, Inc. Investors Business Wire
02:52PM  Why Arrowhead Pharmaceuticals Inc. Is Plummeting Today at Motley Fool
02:08PM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Arrowhead Pharmaceuticals, Inc. (ARWR) PR Newswire
12:49PM  A Couple Of News Dumps You May Have Missed On Tuesday Night
12:02PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Arrowhead Pharmaceuticals, Inc. -- ARWR Business Wire
09:10AM  Why Arrowhead Pharmaceuticals Shares Are Sliding
Nov-08-16 08:05PM  Arrowhead Pharmaceuticals Provides Update on Heparc-2004 Study Business Wire
Nov-03-16 10:00AM  SBPH: Third Quarter has a Sting to it
Nov-01-16 07:30AM  Arrowhead Pharmaceuticals to Present at Upcoming Conferences Business Wire
Oct-20-16 10:10AM  The Chairmen of 4 Companies Unload Shares, Plus Insider Buying at Lions Gate (LGF) at Insider Monkey
10:00AM  Arrowhead Pharmaceuticals to Present Data on ARC-AAT at The Liver Meeting® Business Wire
Oct-19-16 10:55AM  ETFs with exposure to Arrowhead Pharmaceuticals, Inc. : October 19, 2016
Oct-13-16 12:00PM  Arrowhead (ARWR): Two Collaborations in One Week
08:21AM  Arrowhead Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ARWR-US : October 13, 2016
Oct-11-16 09:41PM  Arrowhead Partners with Spring Bank (ARWR, SBPH) at Investopedia
Oct-07-16 02:05PM  Arrowhead Pharmaceuticals Inc. (ARWR), Spring Bank Pharmaceuticals, Inc. (SBPH) Collaborate On HBV at Insider Monkey
10:28AM  What's Next for Alnylam Pharmaceuticals, Inc. After Its Phase 3 Failure? at Motley Fool
Oct-06-16 04:15PM  Alnylam Halts Drug Testing After 18 Deaths; Value Seen In Cousin Drug -6.52%
02:06PM  Alnylams discontinued late-stage drug put a buzzed-about drug technology in its crosshairs at MarketWatch
07:30AM  Arrowhead and Spring Bank Announce Clinical Collaboration for ARC-520 and SB 9200 in Chronic Hepatitis B Business Wire
Oct-05-16 10:05AM  ETFs with exposure to Arrowhead Pharmaceuticals, Inc. : October 5, 2016
Sep-30-16 11:10AM  Why Arrowhead Pharmaceuticals Stock Spiked Today at Motley Fool
11:10AM  3 Top Stocks Under $10 at Motley Fool
Sep-29-16 03:48PM  Amgen Arrowhead Announce Two Cardiovascular Collaborations (AMGN, ARWR) at Investopedia
03:31PM  ARROWHEAD PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
02:00PM  Arrowhead (ARWR): Collaborations with Amgen for Two Cardiovascular Programs
11:45AM  Arrowhead Pharmaceuticals (ARWR) Stock Surges on Amgen Cardiovascular Drug Partnerships
11:16AM  CORRECTED: mgen and Arrowhead Pharma agree 2 cardiovascular collaborations at MarketWatch
09:56AM  Amgen, Arrowhead team up on gene-therapies for heart disease
07:36AM  Amgen and Arrowhead to develop gene-therapies for heart disease
07:30AM  Amgen And Arrowhead Pharmaceuticals Announce Two Cardiovascular Collaborations PR Newswire
Sep-10-16 05:55PM  Are These 3 Clinical-Stage Biotechs Still Buys After Soaring in August? at Motley Fool
Sep-07-16 07:30AM  Arrowhead Pharmaceuticals Doses First Patient with Hepatitis B in Multiple Ascending Dose Portion of Phase 1/2 Study of ARC-521 Business Wire
Sep-06-16 07:30AM  Arrowhead Pharmaceuticals Initiates Phase 2 Study of ARC-AAT Business Wire
Sep-01-16 07:30AM  Arrowhead Pharmaceuticals to Present at Upcoming September Conferences Business Wire
Aug-23-16 01:30PM  Arrowhead (ARWR) Exited Third Quarter with a Strong Balance Sheet
Aug-19-16 12:37PM  ETFs with exposure to Arrowhead Pharmaceuticals, Inc. : August 19, 2016 +6.23%
Aug-18-16 02:40PM  What Caused Arrowhead Pharmaceuticals to Skyrocket 12.5% Today at Motley Fool +11.36%
01:04PM  ARROWHEAD PHARMACEUTICALS, INC. Financials
Arrowhead Pharmaceuticals, Inc., a biopharmaceutical company, develops novel drugs to treat intractable diseases in the United States. The company utilizes its proprietary Dynamic Polyconjugate platform to develop targeted drugs based on the RNA interference mechanism that silences disease-causing genes. Its ARC-520, an RNAi-based therapeutic that is in Phase IIb clinical efficacy studies to treat chronic hepatitis B virus infection; and ARC-AAT, a novel unlocked nucleobase analog containing RNAi-based therapeutic, which is in Phase Ib clinical trial for the treatment of liver disease associated with alpha-1 antitrypsin deficiency. The company's pre-clinical stage drug candidates include ARC-521, an RNAi-based therapeutic for the treatment of chronic hepatitis B virus; ARC-F12, an RNAi-based therapeutic to treat hereditary angioedema and thromboembolic diseases; ARC-HIF2, an RNAi-based therapeutic to treat renal cell carcinoma; and ARC-LPA, an RNAi-based therapeutic for the treatment of cardiovascular diseases. It also holds patents related to Adipotide for the treatment of obesity and related metabolic disorders. The company has research collaboration and license agreement with Shire AG to develop and commercialize targeted peptide-drug conjugates; and a collaborative agreement with Spring Bank Pharmaceuticals, Inc. to perform studies on Arrowhead's ARC-520 and Spring Bank's SB 9200 for the treatment of chronic Hepatitis B. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GIVEN DOUGLAS BDirectorOct 14Sale6.7212,00080,64070,000Oct 18 07:53 PM
Myszkowski Kenneth AllenChief Financial OfficerAug 23Option Exercise2.016,90013,869122,589Aug 24 06:39 PM
Myszkowski Kenneth AllenChief Financial OfficerAug 23Sale8.006,90055,200115,689Aug 24 06:39 PM
Myszkowski Kenneth AllenChief Financial OfficerAug 22Option Exercise2.0113,10026,331128,789Aug 24 06:39 PM
Myszkowski Kenneth AllenChief Financial OfficerAug 22Sale8.0013,100104,800115,689Aug 24 06:39 PM
Anzalone Christopher RichardChief Executive OfficerJun 30Option Exercise5.0915,77280,2791,117,233Jul 05 06:11 PM
Myszkowski Kenneth AllenChief Financial OfficerDec 30Sale6.1323,347143,11785,000Jan 04 07:19 PM